OSLO, Norway, Oct. 23, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the following presentations by the company's research collaborators at the European Association of Nuclear Medicine annual meeting (EANM; 21-25 October; Vienna, Austria).
Title: Pre-dosing with lilotomab prior to antibody-radionuclide conjugate therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumour to red marrow absorbed dose in non-Hodgkin lymphoma patients Authors: J. Blakkisrud et al.
Title: Involvement of cell cycle checkpoints in the therapeutic efficacy of 177Lu-lilotomab in non-Hodgkin B-cell lymphoma Authors: A. Pichard et al.
Title: FDG uptake at baseline may predict absorbed dose in tumor lesions in indolent Non-Hodgkin lymphoma patients treated with the novel antibody-radionuclide conjugate 177Lu-lilotomab satetraxetan Authors: A. Londalen et al.
In addition, Jostein Dahle, Nordic Nanovector's CSO presented in Pre-Congress Symposium 3 - Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities
Title: PS23 - Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies
The abstracts are available by clicking here
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson)
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector's strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector